TD Waterhouse Canada Inc. Raises Stock Position in Bristol Myers Squibb Company $BMY

TD Waterhouse Canada Inc. increased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 194.9% in the 2nd quarter, Holdings Channel reports. The firm owned 81,526 shares of the biopharmaceutical company’s stock after purchasing an additional 53,881 shares during the period. TD Waterhouse Canada Inc.’s holdings in Bristol Myers Squibb were worth $4,605,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Davis Asset Management L.P. acquired a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $27,000. Swiss RE Ltd. purchased a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at approximately $25,000. Darwin Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at $25,000. Addison Advisors LLC acquired a new position in Bristol Myers Squibb in the second quarter valued at about $32,000. Finally, Bayban acquired a new position in shares of Bristol Myers Squibb in the 4th quarter worth approximately $31,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Citigroup reissued a “neutral” rating and set a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, August 3rd. Wells Fargo & Company set a $65.00 price target on Bristol Myers Squibb and gave the company an “equal weight” rating in a report on Friday, July 31st. Truist Financial restated a “buy” rating and issued a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Guggenheim restated a “buy” rating and set a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Finally, Jefferies Financial Group cut Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $66.06.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a Phase 2 trial evaluating a therapy in depression, expanding its pipeline into a large potential market. Positive clinical progress could provide a new growth opportunity if the treatment demonstrates efficacy and safety. Bristol-Myers Squibb Moves Into Depression Market With New Phase 2 Trial
• Positive Sentiment: Analysts and financial commentators continue to highlight BMY’s relatively low valuation, roughly 3.7% forward dividend yield, strong margins and growth products that are offsetting declines in older medicines. These factors support the stock’s defensive and income-oriented appeal. Bristol Myers Squibb: Still Cheap, Despite What The Chart Says
• Neutral Sentiment: Technical indicators have reportedly turned bullish, while RBC Capital maintained a Hold rating, indicating that analysts see some upside but remain cautious about the company’s outlook. Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?
• Negative Sentiment: Bristol Myers Squibb paused enrollment in its zola-cel autoimmune cell-therapy trials after safety surveillance identified inflammatory side effects. Reports that the pause involved serious safety concerns raised questions about the program’s risk profile, development timeline and broader cell-therapy strategy. What Does Bristol Myers Squibb Trial Pause Mean For Its Pipeline?
• Negative Sentiment: The wider healthcare sector traded lower, adding industry-level pressure to BMY. Investors also continue to monitor legacy-drug declines, including Opdivo, and future Eliquis patent-expiry risks. Sector Update: Healthcare Stocks Decline Friday Afternoon

Insider Buying and Selling at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.05% of the stock is currently owned by company insiders.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $66.85 on Monday. The company has a 50-day simple moving average of $62.92 and a 200-day simple moving average of $59.92. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The company has a market capitalization of $136.56 billion, a PE ratio of 14.72, a P/E/G ratio of 0.32 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts predict that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 3.8%. Bristol Myers Squibb’s payout ratio is presently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.